Christian Schade, Aprea CEO
December 9, 2021 10:11 AM EST
R&D

Strug­gling Aprea wins a re­prieve as FDA lifts one of the holds on their on­ly drug

John Carroll

Editor & Founder

A strug­gling Aprea Ther­a­peu­tics got a boost Thurs­day morn­ing af­ter the biotech re­port­ed that the FDA had lift­ed one of the clin­i­cal holds on its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times